Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Hepatology (Baltimore, Md.)|September 11, 2022
c-Rel-dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesisJack Leslie, Jill E Hunter, Amy Collins, et al.
Cancers|July 14, 2023
Impact of COVID-19 on 1-Year Survival Outcomes in Hepatocellular Carcinoma: A Multicenter Cohort StudyShuell De Souza, Jeffrey Kahol de Jong, Ylenia Perone, et al.
Hepatology Communications|May 16, 2025
Precision-cut tumor slices for modeling hepatocellular carcinoma enable at-scale drug screeningAmy L Collins, Keara Kirkness, Erik Ramon-Gil, et al.
Hepatology (Baltimore, Md.)|June 22, 2021
Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular CarcinomaLaura Torrens, Carla Montironi, Marc Puigvehí, et al.
Communications Biology|March 6, 2024
ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancerRebecca Garnham, Daniel Geh, Ryan Nelson, et al.
Liver Cancer|January 2, 2023
Sulfatase-2 from Cancer Associated Fibroblasts: An Environmental Target for Hepatocellular Carcinoma?Marco Y W Zaki, Sari F Alhasan, Ruchi Shukla, et al.
BMJ Open Gastroenterology|April 22, 2022
COVID-19 and liver cancer: lost patients and larger tumoursDaniel Geh, Robyn Watson, Gourab Sen, et al.
The EMBO Journal|March 25, 2021
Neutrophils induce paracrine telomere dysfunction and senescence in ROS-dependent mannerAnthony Lagnado, Jack Leslie, Marie-Helene Ruchaud-Sparagano, et al.
Gut|April 28, 2022
CXCR2 inhibition enables NASH-HCC immunotherapyJack Leslie, John B G Mackey, Thomas Jamieson, et al.
Pageof 2